Melagatran anticoagulation during haemodialysis—‘Primum non nocere’

Michael J. Flanigan

University of Iowa Hospitals, Iowa City, USA

Correspondence and offprint requests to: Michael J. Flanigan, Department of Internal Medicine, University of Iowa Hospitals, Iowa City, IA 52242-4060, USA. Email: michael-flanigan{at}uiowa.edu

‘Primum non nocere’ or ‘First do no harm’ is attributed to Galen's translation of the Hippocratic Corpus (Epidemics, Bk. I, Sect. XI.), ‘Declare the past, diagnose the present, foretell the future; practice these acts. As to diseases, make a habit of two things—to help, or at least to do no harm’ [1,2].

In this issue of Nephrology Dialysis Transplantation, Per-Ola Attman and colleagues describe an elegant, heparin-free, haemodialysis anticoagulation scheme using the direct thrombin inhibitor melagatran. They use dialysate as a drug delivery vehicle and thus regulate melagatran serum levels with precision. The authors define and monitor efficacy and safety end-points. Drug efficacy is assessed by inspecting the dialysis system for clotting, recording dialyser iohexol clearance and monitoring trans-dialyser pressure gradients. Drug safety is assessed by measuring post-dialysis needle puncture haemostasis times. The report includes both intra- and inter-dialysis pharmacokinetic data [3]. The authors note that melegatran is dialysable, has no antidote and might potentiate bleeding. They propose that the prolonged melagatran half-life following dialysis (14±4 h) may facilitate arteriovenous (A-V) fistula and central dialysis catheter patency. They do not, however, announce that surgery, trauma or dental work in the 24 h following dialysis could precipitate uncontrollable haemorrhage [4,5].

Dialysis anticoagulation has a long history. Early dialysis systems exposed blood to variously stagnant and turbulent flow characteristics, bioreactive materials and pyrogenic dialysate. These dialysis systems were intensely thrombogenic, and successful dialysis required through anticoagulation. Initially, the thrombin inhibitor hirudin served this purpose; however, hirudin bio-extraction was laborious, its purity questionable and the leaches needed for extraction fell into shortage during the war years. Thus, human dialysis remained impractical until the description and extraction of heparin became reality [6–8]. Through the 1950s and into the 1980s, the dominant feature of dialyses anticoagulation was bleeding, and ‘uraemic bleeding’ was a major contributor to patient death [9]. Subdural haematomas, haemorrhagic pericarditis, retroperitoneal haematomas and gastrointestinal haemorrhage were believed to be manifestations of uraemic coagulopathy and, while currently less prevalent, remain important contributors to patient morbidity and mortality [10]. Over the last 20 years, improved equipment and nursing practices have permitted heparin doses to decrease from >20 000 units/dialysis to ~5000 units/dialysis, and ‘spontaneous’ bleeding complications have become unusual. Recent cases of spontaneous bleeding after recombinant hirudin haemodialysis anticoagulation illustrate the problems of protracted aggressive anti-thrombin therapy [4], and trials of xilomegatran for the prevention of post-operative venous thrombosis report severe bleeding incidences as high as 5% when therapeutic doses of xilomegatran are administered in the post-operative setting [11]. Of still greater concern is that neither dialysis patients nor their dentists and primary care physicians routinely consider haemodialysis synonymous with systemic anticoagulation. This is likely to result in the unexpected discovery of dialysis-induced coagulopathy and will endanger patient safety whether it occurs during accidental trauma, elective surgery or spontaneously [5].

It is important to maintain perspective and ‘Primum non nocere’. Dialysers are disposable, patients are not. Successful routine haemodialysis is readily achieved in >90% of treatments with no anticoagulant [12–15], while supervised, controlled anticoagulation of dialysis patients with aspirin, clopidogrel, heparin, warfarin, hirudin and low molecular weight heparins leads to excessive bleeding [5,16–22] in 5–10% of dialysis patients annually. It is imperative that innovators alert their readers not just to potential benefits but also to possible risks and hazards. Those who fail to educate their audience fully share responsibility for those adverse events encountered by their ‘trainees’.

Conflict of interest statement. None declared.

[See related Article by Attman et al., pp. 1889]



   References
 Top
 References
 

  1. Primum non nocere. Viewed 5/7/05 @ http://en.wikipedia.org/wiki/Primum_non_nocere
  2. Smith CM. Origin and uses of primum non nocere—above all, do no harm! J Clin Pharmacol 2005; 45: 371–377[Abstract/Free Full Text]
  3. Eriksson UG, Johansson S, Attman PO et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 2003; 42: 743–753[ISI][Medline]
  4. Muller A, Huhle G, Nowack R, Birck R, Heene DL, van der Woude FJ. Serious bleeding in a haemodialysis patient treated with recombinant hirudin. Nephrol Dial Transplant 1999; 14: 2482–2483[Free Full Text]
  5. Karaaslan H, Peyronnet P, Benevent D, Lagarde C, Rince M, Leroux-Robert C. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant 2001; 16: 2072–2074[Abstract/Free Full Text]
  6. Drukker W. Hemodialysis: a historical review. In: Drukker W, Parsons FM, Maher JF, eds. Replacement of Renal Function by Dialysis, 2nd edn. Martinus Nijoff Publishers, Boston; 1983: 8–12
  7. Fagette P. Hemodialysis 1912–1945: no medical technology before its time: part II. ASAIO J 1999; 45: 379–391[ISI][Medline]
  8. Benedum J. The early history of the artificial kidney. Anasthesiol Intensivmed Notfallmed Schmerzther 2003; 38: 681–688[CrossRef][ISI][Medline]
  9. Blagg CR. Acute complications associated with hemodialysis. In: Drukker W, Parsons FM, Maher JF, eds. Replacement of Renal Function by Dialysis, 2nd edn. Martinus Nijoff Publishers, Boston; 1983: 620–621
  10. Kitamura M, Shimbo T, Hida M, Saitoh H, Satoh T. Autopsy findings in maintenance hemodialysis patients. Tokai J Exp Clin Med 1984; 9: 217–222[Medline]
  11. Bergqvist D. Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management. Eur J Haematol 2004; 73: 227–242[CrossRef][ISI][Medline]
  12. Schwab SJ, Onorato JJ, Sharar LR, Dennis PA. Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med 1987; 83: 405–410[CrossRef][ISI][Medline]
  13. Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ. Heparin free dialysis: comparative data and results in high risk patients. Kidney Int 1987; 31: 1351–1355[ISI][Medline]
  14. Romao JE Jr, Fadil MA, Sabbaga E, Marcondes M. Haemodialysis without anticoagulant: haemostasis parameters, fibrinogen kinetic, and dialysis efficiency. Nephrol Dial Transplant 1997; 12: 106–110[Abstract]
  15. Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP. Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol 2004; 62: 29–34[ISI][Medline]
  16. Vazquez E, Sanchez-Perales C, Garcia-Cortes MJ et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol 2003; 87: 135–139[CrossRef][ISI][Medline]
  17. Kaufman JS, O’Connor TZ, Zhang JH et al. Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14: 2313–2321[Abstract/Free Full Text]
  18. Obialo CI, Conner AC, Lebon LF. Maintaining patency of tunneled hemodialysis catheters—efficacy of aspirin compared to warfarin. Scand J Urol Nephrol 2003; 37: 172–176[CrossRef][ISI][Medline]
  19. Moritz ML, Vats A, Ellis D. Systemic anticoagulation and bleeding in children with hemodialysis catheters. Pediatr Nephrol 2003; 18: 68–70[CrossRef][ISI][Medline]
  20. Crowther MA, Clase CM, Margetts PJ et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002; 13: 2331–2337[Abstract/Free Full Text]
  21. Bhasin HK, Dana CL. Spontaneous retroperitoneal hemorrhage in chronically hemodialyzed patients. Nephron 1978; 22: 322–327[ISI][Medline]
  22. Tarjan J, Gofman L, Boros G, Samik J, Mark B, Karatson A, Schwartz J. Haemorrhagic pericarditis and cardiac tamponade during chronic haemodialysis. Int Urol Nephrol 1976; 8: 79–85[Medline]

Related articles in NDT:

Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia
Per-Ola Attman, Pia Ottosson, Ola Samuelsson, Ulf G. Eriksson, Maria Eriksson-Lepkowska, and Gunnar Fager
NDT 2005 20: 1889-1897. [Abstract] [FREE Full Text]  




This Article
Extract
FREE Full Text (PDF)
All Versions of this Article:
20/9/1789    most recent
gfi016v1
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Related articles in NDT
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Flanigan, M. J.
PubMed
PubMed Citation
Articles by Flanigan, M. J.